Anticardiolipin antibodies are not an independent risk factor for stroke: An incident case-referent study nested within the MONICA and Vasterbotten Cohort Project

Stroke

Volumn 31, Issue 6, 2000, Pages 1289-1293

  Ahmed, Ejaz ^a   Stegmayr, Birgitta ^b   Trifunovic, Jasmina ^a   Weinehall, Lars ^b   Hallmans, Göran ^b   Lefvert, Ann Kari ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoantibodies; Cardiolipins; Cerebrovascular disorders; Epidemiology; Phospholipids

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; WORLD HEALTH ORGANIZATION;

EID: 0034085153     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.6.1289     Document Type: Article

References (36)

1. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet. 1993;342:341-344.
2. Vaarala O, Mänttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.
3. Buchanan NM, Khamashta MA, Morton KE, Kerslake S, Baguley EA, Hughes GR. A study of 100 high risk lupus pregnancies. Am J Reprod Immunol. 1992;28:192-194.
4. Årfors L, Winiarski J, Lefvert AK. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur J Haematol. 1996;56:230-234.
5. Zielinska J, Ryglewicz D, Wierzchowska E, Lechowicz W, Hier DB, Czlonkowska A. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res. 1999;21:653-657.
6. Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet. 1994;344:452-456.
7. Tuhrim S, Rand JH, Wu X-X, Weinberger J, Horowitz DR, Goldman ME, Godbold JH. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561-1565.
8. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069-2073.
9. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117: 997-1002.
10. Szczepanski M, Cieslak E, Gardas A, Bauer A, Majkowski J. Prevalence of high IgM anticardiolipins in patients with ischemic stroke. Eur J Neurol. 1998;5:287-290.
11. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisløff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet. 1992;339: 451-453.
12. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler J, Alam Z, Carey JL. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death: a prospective cohort study. Stroke. 1997;28:1660-1665.
13. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology. 1997;48:91-94.
14. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke. 1998;29:2245-2253.
15. Munts AG, van Genderen P JJ, Dippel WJ D, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol. 1998;245:21-25.
16. Tunstall-Pedoe H, for the WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring of trends and determinants in cardiovascular diseases): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
17. Weinehall L, Hallgren C-G, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care. 1998; 16:171-176.
18. Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology. 1992;11:204-213.
19. Stegmayr B, Asplund K, Wester PO. Trends in incidence, case-fatality rate, and severity of stroke in northern Sweden, 1985-1991. Stroke. 1994;25:1738-1745.
20. Harris EN. The Second International Anti-cardiolipin Standardization workshop: the Kingston Anti-phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol. 1990;94:476-484.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons Inc; 1989.
22. Lai SM, Alter M, Friday G, Sobel E. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke. 1994;25:958-962.
23. Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price TR, Wolf PA. Stroke recurrence within 2 years after ischemic infarction. Stroke. 1991;22:155-161.
24. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke: a population perspective. Diabetologia. 1995;38:1061-1068.
25. Eber B. Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. Cardiology. 1992;80:156. Letter.
26. Vayssairat M, Abuaf N, Gaitz JP, Baudot N. Antiphospholipids: a "guilty ghost" syndrome. Clin Rev Allergy Immunol. 1995;13:1-4. Editorial.
27. Mattila K, Vaarala O, Palosuo T, Malkamäki M, Valtonen V, Nieminen M, Aho K. Serologic response against cardiolipin and enterobacterial common antigen in young patients with acute myocardial infarction. Clin Immunol Immunopathol. 1989;51:414-418.
28. Cheng H-W. Pathogenicity of antiphospholipid antibodies. In: Immunophysiology of Antiphospholipid Antibodies. Austin, Tex: RG Landes Co; 1994:67-89.
29. Brey RL, Coull BM. Antiphospholipid antibodies: origin, specificity, and mechanism of action. Stroke. 1992;23(suppl I):I-15-I-18.
30. Hess DC, Sheppard JC, Adams RJ. Increased immunoglobin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke. 1993;24:994-999.
31. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol. 1992;10: 455-460.
32. Ahmed E, Nityanand S, Mustafa A, Brismar K, Lefvert AK. Anticardiolipin antibodies and circulating immune complexes in type 1 diabetes mellitus: increased prevalence and relation to vascular complications. Clin Exp Immunol. 1999;115:255-259.
33. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
34. Greaves M. Coagulation abnormalities and cerebral infarction. J Neurol Neurosurg Psychiatry. 1993;56:433-439.
35. Toschi V, Motta A, Castelli C, Paracchini ML, Zerbi D, Gibelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke. 1998;29:1759-1764.
36. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17:3159-3163.